PMID- 22066978
OWN - NLM
STAT- MEDLINE
DCOM- 20130130
LR  - 20151119
IS  - 1755-3768 (Electronic)
IS  - 1755-375X (Linking)
VI  - 90
IP  - 2
DP  - 2012 Mar
TI  - Comparison of cytokine levels from undiluted vitreous of untreated patients with 
      retinal vein occlusion.
PG  - e98-e103
LID - 10.1111/j.1755-3768.2011.02292.x [doi]
AB  - PURPOSE: To compare cytokines in undiluted vitreous of treatment-naive patients 
      with macular oedema without vitreomacular traction secondary to branch (BRVO), 
      central (CRVO) and hemi-central (H-CRVO) retinal vein occlusion. METHODS: 
      Ninety-four patients (median age 72 years, 42 men) underwent an intravitreal 
      combination therapy, including a single-site 23-gauge core vitrectomy and the 
      application of bevacizumab and dexamethasone due to vision-decreasing macular 
      oedema. Among these were 43 patients with BRVO, 35 with CRVO and 16 patients with 
      hemi-CRVO, which were distributed in a fresh or old retinal vein occlusion type 
      (seven or more months after onset). Undiluted vitreous samples were analysed for 
      interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and vascular 
      endothelial growth factor (VEGF-A) with cytometric BEAD assay. Vitreous samples 
      from patients with idiopathic epiretinal membrane served as controls (n = 14). 
      RESULTS: The mean cytokine values were highest in the CRVO group with IL-6 = 64.7 
      pg/ml (SD +/- 115.8), MCP-1 = 1015.8 pg/ml (+/-970.1) and VEGF-A = 278.4 pg/ml 
      (+/-512.8), followed by the H-CRVO group with IL-6 = 59.9 pg/ml (SD +/- 97.5), MCP-1 
      = 938.8 pg/ml (+/-561.1) and VEGF-A = 211.5 pg/ml (+/-232.4). The BRVO group had IL-6 
      = 23.2 pg/ml (SD +/- 48.8), MCP-1 = 602.6 g/ml (+/-490.3) and VEGF-A = 161.8 pg/ml 
      (+/-314.4). The values of MCP-1 and VEGF-A were significantly different for CRVO or 
      H-CRVO versus BRVO. All values were significantly higher than in the control 
      samples, which had 6.2 +/- 3.4 pg/ml (IL-6), 253 +/- 74 pg/ml (MCP-1) and 7 +/- 4.9 
      pg/ml (VEGF-A). Within the old RVO type, only MCP-1 was significantly different 
      for CRVO or H-CRVO versus BRVO. CONCLUSIONS: Both inflammatory markers and VEGF-A 
      were higher in CRVO and H-CRVO than in BRVO undiluted vitreous samples. It seems 
      that monocyte recruitment to the vessel wall, which might underlie the importance 
      of eosinophils in tissue remodelling after RVO, is of special interest owing to 
      the significant difference in MCP-1 in the older RVO types.
CI  - (c) 2011 The Authors. Acta Ophthalmologica (c) 2011 Acta Ophthalmologica Scandinavica 
      Foundation.
FAU - Koss, Michael J
AU  - Koss MJ
AD  - Department of Ophthalmology, Section of Vitreo-Retinal Surgery, Goethe 
      University, 60590 Frankfurt am Main, Germany. Michael.Koss@me.com
FAU - Pfister, Marcel
AU  - Pfister M
FAU - Rothweiler, Florian
AU  - Rothweiler F
FAU - Michaelis, Martin
AU  - Michaelis M
FAU - Cinatl, Jindrich
AU  - Cinatl J
FAU - Schubert, Ralf
AU  - Schubert R
FAU - Koch, Frank H
AU  - Koch FH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111108
PL  - England
TA  - Acta Ophthalmol
JT  - Acta ophthalmologica
JID - 101468102
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glucocorticoids)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Bevacizumab
MH  - Chemokine CCL2/*metabolism
MH  - Dexamethasone/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Flow Cytometry
MH  - Fluorescein Angiography
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Interleukin-6/*metabolism
MH  - Intravitreal Injections
MH  - Macular Edema/drug therapy/etiology/*metabolism
MH  - Male
MH  - Retinal Vein Occlusion/complications/drug therapy/*metabolism
MH  - Vascular Endothelial Growth Factor A/*metabolism
MH  - Vitrectomy
MH  - Vitreous Body/*metabolism
EDAT- 2011/11/10 06:00
MHDA- 2013/01/31 06:00
CRDT- 2011/11/10 06:00
PHST- 2011/11/10 06:00 [entrez]
PHST- 2011/11/10 06:00 [pubmed]
PHST- 2013/01/31 06:00 [medline]
AID - 10.1111/j.1755-3768.2011.02292.x [doi]
PST - ppublish
SO  - Acta Ophthalmol. 2012 Mar;90(2):e98-e103. doi: 10.1111/j.1755-3768.2011.02292.x. 
      Epub 2011 Nov 8.